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Abstract
Background: Electromagnetic navigation bronchoscopy (ENB) is an image-guided, minimally invasive approach that
uses a flexible catheter to access pulmonary lesions.
Methods: NAVIGATE is a prospective, multicenter study of the superDimension™ navigation system. A prespecified
1-month interim analysis of the first 1,000 primary cohort subjects enrolled at 29 sites in the United States and Europe
is described. Enrollment and 24-month follow-up are ongoing.
Results: ENB index procedures were conducted for lung lesion biopsy (n = 964), fiducial marker placement (n = 210),
pleural dye marking (n = 17), and/or lymph node biopsy (n = 334; primarily endobronchial ultrasound-guided). Lesions
were in the peripheral/middle lung thirds in 92.7%, 49.7% were <20 mm, and 48.4% had a bronchus sign. Radial EBUS
was used in 54.3% (543/1,000 subjects) and general anesthesia in 79.7% (797/1,000). Among the 964 subjects (1,129
lesions) undergoing lung lesion biopsy, navigation was completed and tissue was obtained in 94.4% (910/964). Based
on final pathology results, ENB-aided samples were read as malignant in 417/910 (45.8%) subjects and non-malignant
in 372/910 (40.9%) subjects. An additional 121/910 (13.3%) were read as inconclusive. One-month follow-up in this
interim analysis is not sufficient to calculate the true negative rate or diagnostic yield. Tissue adequacy for genetic
testing was 80.0% (56 of 70 lesions sent for testing). The ENB-related pneumothorax rate was 4.9% (49/1,000) overall
and 3.2% (32/1,000) CTCAE Grade ≥2 (primary endpoint). The ENB-related Grade ≥2 bronchopulmonary hemorrhage
and Grade ≥4 respiratory failure rates were 1.0 and 0.6%, respectively.
Conclusions: One-month results of the first 1,000 subjects enrolled demonstrate low adverse event rates in a generalizable
population across diverse practice settings. Continued enrollment and follow-up are required to calculate the true negative
rate and delineate the patient, lesion, and procedural factors contributing to diagnostic yield.
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Background
Guidelines for lung nodule evaluation recommend the least
invasive approach given each patient’s clinical presentation
[1]. Utilization of electromagnetic navigation bronchoscopy
(ENB) has increased over the past ten years as a minimally
invasive approach to complement traditional bronchoscopy,
endobronchial ultrasound (EBUS), and image-guided
transthoracic biopsy. Selection of the most appropriate
diagnostic modality based on patient comorbidities and
lesion location is critical to provide the fastest, safest,
and most complete diagnosis possible.
Seventeen published studies of ENB use have been
summarized in three recent meta-analyses [2–4]. Pneumo-
thorax is the most common complication, occurring in
approximately 3% of patients [2], lower than the pooled
20% rate reported for transthoracic needle biopsy [5]. How-
ever, published studies have typically been small, single-
center, retrospective, and mostly conducted by expert users.
The safety, usage profile, and clinical utility of ENB in a
large, prospective, multicenter, generalizable population is
unknown. The pragmatic design [6] of NAVIGATE maxi-
mizes patient eligibility, usual care settings, flexibility of
adherence, and a relevant primary outcome for clinical
practice. The detailed prospective collection of data
also minimizes retrospective bias and allows future
multivariate analyses to provide more meaningful infor-
mation on the variable utilization of this technology into
real-world practice and its impact on measurable out-
comes, such as diagnostic yield and risk. Furthermore, a
heterogeneous dataset will be instructive for the design of
potential comparative studies with respect to operator
training, subject inclusion criteria, data to be collected,
definitions, and expected complication rates.
The primary objectives of this protocol-specified 1,000-
subject, 1-month interim analysis of the NAVIGATE study
[7] are to present the preliminary safety, clinical usage pat-
terns, and performance of ENB in a large, unrestricted,
generalizable population across diverse practice settings.
The interim data will provide an early look at typical
patient and lesion characteristics and procedural standard-
of-care, generating questions for future NAVIGATE
analyses and new clinical studies. Enrollment and con-
tinued follow-up are ongoing.
Methods
NAVIGATE is a prospective, multicenter, global, single-
arm, cohort study in subjects undergoing ENB procedures.
Enrollment of up to 1,500 subjects is planned at 37 sites in
the United States and Europe. Subjects evaluations
occur at baseline (within 30 days of the procedure), on
the procedure day, and at 1 month, 12 months, and
24 months post-procedure. This manuscript describes
the results of a prespecified 1-month interim analysis of
the first 1,000 subjects enrolled at 29 sites in the United
States and Europe. Enrollment and 12- and 24-month
follow-up are ongoing. Brief methods are included
below. A full list of study assessments and definitions is
included in Additional files 1 and 2. The study design
has been published [7].
Inclusion criteria are intentionally broad to ensure
external validity. All consecutive, consented adult patients,
who are not pregnant or nursing, and who are candidates
for an elective ENB procedure based on physician dis-
cretion per recommended guidelines and institutional
standard-of-care, are eligible. A maximum of 75 subjects
is allowed per site. All investigators must have prior ENB
experience. Investigators without extensive experience
may enroll a maximum of five “roll-in” cases, which are
excluded from this interim analysis. Roll-in cases will be
included in the 1-year and 2-year analyses of the full en-
rollment when a more complete evaluation of the impact
of user experience on diagnostic yield and other outcomes
can be conducted.
All ENB procedures use the superDimension™ navigation
system [8, 9] version 6.0 or higher (Medtronic, Minneapolis,
MN) per product instructions and institutional standard
practice. All complementary tools and procedures, including
choice of catheter and biopsy tools, order of biopsy tool use,
and strategy for staging and diagnostic bronchoscopy
were performed at clinician discretion and were cap-
tured prospectively for data analysis.
The primary endpoint is pneumothorax related to
the ENB index procedure rated Grade ≥2 according to
the validated Common Terminology Criteria for Ad-
verse Events (CTCAE) scale [7, 10], as adjudicated by
an independent medical monitor. Pneumothorax was
protocol-specified as the primary endpoint because it
is applicable to all ENB procedures, including lung
lesion biopsy, lymph node biopsy, fiducial placement,
and pleural dye marking. Major secondary endpoints
were all ENB-related pneumothorax, bronchopulmonary
hemorrhage, and respiratory failure. Other secondary
endpoints reported at 1 month were subject self-
reported satisfaction with the procedure; adequacy of
samples for molecular testing and mutation type; accur-
ate fiducial placement as assessed by follow-up imaging;
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and success rate of pleural dye marking demonstrated
by surgical resection [7].
Diagnostic yield of the ENB index procedure will be
calculated at the 12- and 24-month follow-up as the
proportion of subjects with a definitive diagnosis (final
pathology of the ENB-aided sample). One-month follow-up
in this interim analysis is not sufficient to calculate the true
negative rate or diagnostic yield. All lung nodules evaluated
during the ENB index procedure will be followed for con-
firmation. Sensitivity, specificity, negative predictive value,
and positive predictive value will be published beginning
with the 12-month follow-up.
No sample size calculations were conducted for this
single-arm, observational study. Analyses were performed
using SAS® Version 9.4 (SAS Inc., Cary, NC). Data are
summarized by descriptive statistics, including frequency
distributions and cross-tabulations for discrete variables
and mean, standard deviation, median, minimum, and
maximum values for continuous variables. At least 10% of




This prespecified interim analysis includes the first
1,000 primary cohort subjects enrolled at 29 clinical
sites in the United States (27 sites) and Europe (two
sites) from April 16, 2015 to June 27, 2016 (Fig. 1, and
Additional file 3). Enrollment ranged from 2 to 75 subjects
per site. Site types include academic centers (11 sites), pri-
vate practice (11 sites), and mixed academic/private prac-
tice (seven sites). One-month follow-up was completed in
93.3% of subjects. Chronic obstructive pulmonary disease
was present in 44.8%. Approximately one-third of subjects
had a history of prior invasive lung procedures (Table 1).
Procedural characteristics
One thousand ENB index procedures were conducted
in 1,000 subjects. Procedures were conducted for one
or more purposes, including lung lesion biopsy (n = 964
Fig. 1 Flow Diagram. As of June 27, 2016, 1,000 primary cohort
subjects had been enrolled into the NAVIGATE study and comprise
the first protocol-specified interim analysis of the 1-month results.
The primary cohort is defined per protocol as those subjects who
undergo an ENB index procedure minus roll-in subjects [7]. One-month
follow-up is complete in 933/1,000 subjects (93.3%)
Table 1 Subject demographics (all primary cohort subjects)
N = 1000 Subjects




Black or African American 12.5% (125/1000)
Asian 0.6% (6/1000)
American Indian or Alaska Native 0.4% (4/1000)




Unable To Report 0.1% (1/1000)
Hispanic or Latino Ethnicity 4.4% (44/1000)
Tobacco History (Current or Former) 80.8% (807/999)
COPD 44.8% (448/999)
FEV1 (% of predicted) 74.8 ± 25.6 (332) [75.5] (20.0–140.0)
FEV1/FVC Ratio 0.9 ± 0.2 (331) [0.9] (0.3–1.9)
DLCO (% of predicted) 66.4 ± 24.9 (225) [66.0] (6.0–141.0)
Asthma 12.6% (126/999)
Prior Invasive Lung Proceduresa 30.6% (306/1000)
Bronchoscopy 20.4% (204/1000)
Standard Bronchoscopy 12.3% (123/1000)
Image-guided Bronchoscopyb 9.7% (97/1000)
Transthoracic Needle Aspiration 5.1% (51/1000)
Surgery 11.1% (111/1000)
Other 3.0% (30/1000)
Personal History of Cancer 45.8% (458/999)





Prescription Antiplatelet 6.8% (68/1000)
Aspirin 32.5% (325/1000)
Other 1.4% (14/1000)
Data are presented as n/N (%) or mean ± standard deviation (n) [median] (range)
Acronyms: COPD chronic obstructive pulmonary disease, DLCO diffusing
capacity of the lung for carbon monoxide, FVC forced vital capacity, FEV1
forced expiratory volume in 1 s, EBUS endobronchial ultrasound, ENB
electromagnetic navigation bronchoscopy
aEach subject could have multiple prior procedures
bIncludes 2.3% (23/1000) standard bronchoscopy with EBUS, 2.8% (28/1000)
superDimension ENB, 2.6% (26/1000) superDimension ENB with EBUS,
0.8% (8/1000) other navigation bronchoscopy, and 1.8% (18/1000) other
navigation bronchoscopy with EBUS
cSubjects could have multiple antithrombotic medications. “Other” includes
nonsteroidal anti-inflammatory drugs, fish oil, and vitamins
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subjects), fiducial marker placement (n = 210), pleural
dye marking (n = 17), and/or lymph node biopsy (n =
334; primarily guided by linear EBUS), as shown in
Fig. 2. General anesthesia was used in 79.7% of subjects.
Radial EBUS was used during the ENB index procedure
in 54.3% (543/1,000) and fluoroscopy was used in 90.1%
(1,017/1,129) of lesions. The median ENB procedure
time was 25.0 min (interquartile range 14.0–41.0 min).
See Table 2 for other procedural characteristics. Overall,
94.8% (827/872) of subjects reported that their expecta-
tions for the procedure we adequately met.
Safety
Pneumothorax CTCAE Grade ≥2 occurred in 32/1,000
subjects (3.2%; Table 3). Any-grade pneumothorax occurred
in 49 subjects (4.9%). Bronchopulmonary hemorrhage was
1.0% CTCAE Grade ≥2 (10/1,000) and 2.3% overall (23/
1,000). CTCAE Grade ≥4 respiratory failure occurred in 6/
1,000 (0.6%). As of the 1-month follow-up (which allowed a
visit window up to 37 days post-ENB), 23 subjects had died
(six completed the 1-month visit; 17 did not). No deaths
were considered related to the ENB device or associated
tools by either the clinical investigator or the independent
medical monitor. There was one procedure-related death
due to Grade 5 hypoxic respiratory failure 9 days after the
ENB index procedure, deemed related to complications of
general anesthesia, in a patient with multiple comorbidities,
including cirrhosis, hepatocellular carcinoma, small cell
carcinoma, and ovarian cancer.
Lung lesion biopsies
Among the 964 subjects (1,129 lesions) undergoing
lung lesion biopsy, the median lesion size was 20.0 mm
(interquartile range: 16.0 mm [Q1: 14.0, Q3: 30.0]), and
49.7% of lesions were <20 mm in diameter (Table 4). Most
lesions were in the peripheral (62.6%) or middle (30.1%)
lung thirds. An airway to the lesion was visible on pre-
procedure CT (bronchus sign) in 48.4%.
ENB was able to navigate successfully to allow a tissue
biopsy (according to subjective operator assessment) in
910 subjects (94.4%) and 1,036 lesions (91.8%; Table 5).
Rapid on-site evaluation (ROSE) for immediate peri-
procedural feedback on pathology specimens was con-
ducted in 66.1% (601/909) of subjects. Among 247 lesions
diagnosed with primary lung adenocarcinoma or non-
small-cell lung cancer not otherwise specified, molecular
genetic testing was attempted in 70/247 (28.3%), with
adequate tissue in 56/70 (80.0%; Table 5).
Based on the final pathology results of the ENB index
procedure, tissue was interpreted as malignant in 417/
910 (45.8%) subjects (Table 6). Primary lung cancer was
diagnosed in 40.1% of subjects. Preliminary clinical stage
[11] in subjects diagnosed with primary lung cancer was
52.9% Stage I, 10.7% Stage II, 18.9% Stage III, and 17.3%
Stage IV (Fig. 3), to be confirmed with follow-up. Lymph
node biopsies were attempted during the ENB index
procedure (same anesthetic event) in 33.4% of cases
(334/1,000). In 322/334 (96.4%) of these cases, medias-
tinal staging was conducted using linear EBUS. Lymph
node biopsy was guided by ENB in 42 cases (alone or in
combination with linear EBUS).
Based on site-reported assessments of the ENB-aided
final pathology sample, tissue was interpreted as non-
malignant in 372/910 (40.9%) subjects (Table 6). An
additional 121/910 (13.3%) were interpreted as incon-
clusive. Longer follow-up is required to confirm true
Fig. 2 Reasons for Conducting ENB on a Per Subject Basis. The NAVIGATE ENB index procedure could be conducted for more than one purpose
in the same anesthetic event, including lung lesion biopsy, fiducial marker placement, pleural dye marking, or lymph node biopsy. Not drawn to
scale. Not shown in graph: ENB-guided fiducial marker placement plus lymph node biopsy (n = 10); ENB-guided fiducial marker placement plus
lymph node biopsy plus ENB-guided pleural dye marking (n = 0)
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versus false negatives and calculate diagnostic yield. At
this time, the true prevalence of malignancy in the
patient population is unknown.
Fiducial placement and pleural dye marking
A total of 417 fiducial markers were placed in 210 sub-
jects. Subjective operator assessment of accurate fiducial
placement was 208/210 (99.0%) and fiducial markers were
still present at follow-up imaging in 192/205 (93.7%). In
subjects undergoing fiducial marker placement, ENB-
related adverse events included eight pneumothoraces
CTCAE Grade ≥2 (3.8%), three respiratory failures
CTCAE Grade ≥4 (1.4%), and one bronchopulmonary
hemorrhage Grade 1. Pleural dye marking was con-
ducted in 17 subjects, of which 15 (88.2%) were consid-
ered adequate for surgical resection.
Discussion
Lung cancer causes one quarter of all cancer deaths,
representing a significant public health problem [12].
Table 3 Adverse events related to the ENB index procedure or
devices (1 Month Follow-up)a
N = 1000 Subjects
Pneumothorax
CTCAE Grade 2 or Higher 3.2% (32/1000)
All Grades 4.9% (49/1000)
Bronchopulmonary Hemorrhage
CTCAE Grade 2 and Higher 1.0% (10/1000)
All Grades 2.3% (23/1000)
Respiratory Failure, CTCAE Grade 4 or Higher 0.6% (6/1000)
Death (anesthesia-related respiratory failure 9 days
post-ENB)b
0.1% (1/1000)
Data are presented as % (n/N subjects)
Acronyms: CTCAE Common Terminology Criteria for Adverse Events, ENB
electromagnetic navigation bronchoscopy
aOther than expected observations associated with anesthesia (e.g., common
or expected post-procedure pain, transient nausea, transient emesis,
post-procedure constipation)
bGrade 5 hypoxic respiratory failure 9 days after the ENB index procedure,
deemed related to complications of general anesthesia, in a patient with
multiple comorbidities, including cirrhosis, hepatocellular carcinoma, small cell
carcinoma, and ovarian cancer. As of 1-month follow-up, a total of 23 subjects
had died (6 completed 1-month follow-up visit; 17 did not). As of the 1-month
follow-up, no other deaths were considered related to the ENB device or associated
tools by either the clinical investigator or the independent medical monitor
Table 2 General procedural characteristics (all primary cohort
subjects)
N = 1000 Procedures
General Anesthesia 79.7% (797/1000)
Moderate Sedation 20.3% (203/1000)
ENB Software Version
Version 6 18.4% (184/1000)
Version 7 81.6% (816/1000)
Radial EBUS used During ENB Procedurea 54.3% (543/1000)
Cone Beam CT used 5.4% (54/1000)
Total Procedure Time (Bronchoscope In/Out),
min
52.0 (36.0 [35.0–71.0])
ENB Procedure Time (Locatable Guide In/Out),
minb
25.0 (27.0 [14.0–41.0])
Data are presented as n/N (%) or median (interquartile range [Q1-Q3])
Acronyms: CT computed tomography, EBUS endobronchial ultrasound, ENB
electromagnetic navigation bronchoscopy
aOther than for lymph node biopsy but including all biopsy, fiducial, and
pleural dye marking procedures
bData only available for 499 subjects, because question was added to case
report forms after enrollment had begun
Table 4 Lung lesion characteristics (subjects undergoing ENB-
aided biopsy)
N = 1129 Lesions in 964
Subjects
Pre-test probability of malignancy
(physician estimation)
67.1 ± 26.5 (790) [75.0]
(0.0–100.0)
Pre-test probability of malignancy
(Swenson’s equation)a
61.6 ± 29.4 (789) [67.1]
(2.9–100.0)
Average Lung Lesion Size, mm
Mean ± SD (N) 23.6 ± 14.4 (1129)
Median, Range (min-max) 20.0 (3.0–118.0)
Interquartile Range (Q1-Q3) 16.0 (14.0–30.0)
< 20 mm 49.7% (561/1129)
≥ 20 mm 50.3% (568/1129)
Lesion Location
Right Upper Lobe 31.7% (358/1129)
Right Middle Lobe 8.1% (91/1129)
Right Lower Lobe 19.0% (215/1129)
Left Upper Lobe 25.9% (292/1129)
Left Lower Lobe 15.3% (173/1129)
Lung Zoneb
Peripheral third of lung on CT 62.6% (707/1129)
Middle third of lung on CT 30.1% (340/1129)
Proximal third of lung on CT 7.3% (82/1129)
Lesion Visible on Fluoroscopy 60.0% (610/1017)
Ground Glass Lesions (Suzuki
Class 1 or 2) [28]
6.3% (71/1123)
Spiculated Lesion Border 60.9% (687/1128)
Bronchus Sign Present on CT 48.4% (546/1129)
Lesion PET Positive (≥2.5 standard
uptake value)
80.9% (479/592)
Data are presented as n/N (%) or mean ± standard deviation (n)
[median] (range)
Acronyms: CT computed tomography, PET positron emission tomography, SD
standard deviation
aPre-test probability of malignancy (calculated): x = −6.8272 + (0.0391 *
“age”) + (0.7917 * “tobacco history”) + (1.3388 * “history of extrathoracic
cancer”) + (0.1274 * “diameter in mm”) + (1.0407 * “spiculation”) + (0.7838 *
“upper lobe”). Not applicable to patients with a diagnosis of cancer that
has been made within the previous 5 years or to patients with previous
lung cancer [29]
bSee Folch et al. 2016 for definitions [7]
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While the incidence has declined in concert with decreased
smoking prevalence, survival rates have improved little over
the past 50–60 years, largely due to a high proportion of
late-stage diagnoses with a 5-year survival rate of only 4%
[12]. Earlier-stage diagnoses will lead to more meaningful
improvements in survival and will require modalities that
allow the accurate sampling of smaller, more peripheral
lung lesions. The National Lung Screening Trial [13] and
screening coverage in select high-risk patients [14] has been
projected to increase low-dose CT utilization by over ten
million procedures annually [15]. However, an extremely
high percentage (96%) of false positive screening results
[13, 16] and the risk of unnecessary procedures requires
the judicious use of minimally invasive options and a care-
ful balance of the risk-to-benefit ratio for further diagnosis
and management [17].
Several current technologies can provide minimally
invasive diagnostic evaluation in appropriately selected
patients, although each has limitations. PET-CT is often
considered the second-line diagnostic option for nodules
detected on CT [18], but is typically not reimbursed for
screening and does not provide tissue diagnosis. Conven-
tional bronchoscopy is safe but is limited to proximal
lesions and has a high non-diagnostic rate, potentially lead-
ing to unnecessary invasive procedures in 20–25% of pa-
tients, including the use of thoracoscopy for diagnostic
wedge resection [19–21]. Image-guided transthoracic
biopsy provides high diagnostic accuracy but at the cost
of pneumothorax rates averaging 20% (range 4 to 62%)
Table 5 Procedural characteristics in lung lesion biopsy cases
N = 1129 Lesions in 964
Subjects
Navigation Success (per lesion)a 91.8% (1036/1129)
Navigation Success (per subject)a 94.4% (910/964)
Number of Lesions Biopsied (per subject) 1.2 ± 0.5 (964) [1.0] (1.0–5.0)
Biopsy Tools Used During ENB Index Procedureb
Aspiration Needle 52.2% (503/964)
Biopsy Forceps 81.2% (783/964)
Cytology Brush 47.0% (453/964)
Needle-Tipped Cytology Brush 20.2% (195/964)
Triple Needle-Tipped Cytology Brush 23.4% (226/964)
GenCut™ Core Biopsy Tool 18.9% (182/964)
Bronchoalveolar Lavage or Washing 37.8% (364/964)
Rapid on-site evaluation (ROSE) usedc 66.1% (601/909)
Molecular/genetic testing attemptedd 28.3% (70/247)
Molecular/genetic testing successful 80.0% (56/70)
Inadequate Sample 20.0% (14/70)
Molecular/genetic testing not attemptedd 71.7% (177/247)
Not Necessary 49.2% (87/177)
Not Standard Practice 41.2% (73/177)
Other 9.6% (17/177)
Data are presented as n/N (%) or mean ± standard deviation (n) [median] (range)
aAble to navigate successfully and allow a tissue biopsy (according to subjective
operator assessment)
bMore than one tool used per procedure
cPer subject, among subjects with an ENB-aided tissue sample obtained. Data
missing for 1 subject
dPer lesion, among 247 lesions with primary adenocarcinoma (n = 233) or
primary non-small-cell lung cancer not otherwise specified (n = 14). More than
one reason could be chosen per lesion
Table 6 Pathology result aided by the index ENB procedurea
N = 910 subjects with navigation complete and tissue sample obtained
Malignant 45.8% (417/910)
Lung cancer 40.1% (365/910)
Non-Small Cell Lung Cancer (NSCLC) 36.4% (331/910)
Adenocarcinoma 23.5% (214/910)
Squamous Carcinoma 11.4% (104/910)
Other NSCLC 1.5% (14/910)
Small Cell Carcinoma 2.9% (26/910)
Neuroendocrine Carcinoma 1.1% (10/910)
Metastatic Carcinoma of Extrathoracic Origin 4.4% (40/910)
Lymphoma 0.2% (2/910)
Malignant Cells (unable to characterize) 0.9% (8/910)
Other 0.3% (3/910)
Site-Reported Non-Malignant or Inconclusive Results
Non-Malignant 40.9% (372/910)
Normal Lung Tissue/Bronchial Epithelium 10.4% (95/910)
Benign Non-Specific 21.9% (199/910)







Atypical Cells 1.9% (17/910)
Lymphocytes 1.1% (10/910)
Organizing Pneumonia 0.8% (7/910)
Interstitial Lung Disease 0.4% (4/910)
Otherc 1.0% (9/910)
Inconclusive 13.3% (121/910)
Data are presented as n/N (%) or mean ± standard deviation (n) (range)
Acronym: ENB electromagnetic navigation bronchoscopy
aPreliminary 1-month results, to be confirmed by subsequent surgery, biopsy,
or radiographic follow-up through 2 years as appropriate per clinician’s assessment
of the patient’s probability of malignancy. One-month follow-up in this
interim analysis is not sufficient to calculate the true negative rate or
diagnostic yield
bIncludes reactive bronchial cells and other nonspecific “benign” diagnoses
cReported as 1 case each of: (1) fibroelastic scar, (2) squamous dysplasia, (3)
squamous metaplasia, (4) radiotherapy changes, (5) blood clots post-FNA, (6)
asbestos fibrosis, (7) benign metastasizing leiomyoma, (8) focally anthracotic
alveolated pulmonary parenchyma, and (9) iron pill aspiration
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[5] and the need for additional procedures to diagnose
and stage mediastinal lymph nodes. ENB provides a min-
imally invasive platform for peripheral lung lesion sam-
pling, concurrent lymph node staging with linear EBUS,
preparation for treatment via fiducial placement or
localization via pleural dye marking in a single procedure.
The primary objective of this interim NAVIGATE
analysis was to evaluate ENB safety. While published
pneumothorax rates are low (3.1% [range 0–13%]) [2],
most prior studies are single-center with fewer than
100 subjects [4, 7]. The current analysis demonstrates
low pneumothorax, bronchopulmonary hemorrhage,
and respiratory failure rates in the context of a large,
diverse study cohort and a wide range of user experience
levels, confirming the safety of advanced bronchoscopy
for the access and sampling of all pulmonary nodules.
Pneumothorax was also infrequent following fiducial
placement (3.8%), in contrast to rates ranging from 22 to
67% following percutaneous fiducial marking [22], Despite
the advanced stage of some of the enrolled subjects, there
were only 23 deaths within the 1-month follow-up time-
frame, further substantiating the safety of the procedure.
Only one death was considered related to the ENB index
procedure, due to general anesthesia in a patient with
multiple comorbidities, and none were related to the ENB
device or associated tools. These results suggest a highly
favorable risk-to-benefit ratio for the use of ENB to aid in
lung lesion biopsies, particularly given the risk profile of
the patients included, with approximately 45% COPD in-
cidence and a relatively high rate of Stage III-IV disease.
A second objective of this analysis was to explore the
real-world usage patterns and clinical utility of ENB. The
interim results elucidate the rates of general anesthesia use
(79.7%), ROSE utilization (66.1%), and concurrent fluoro-
scopic (90.1%) and radial EBUS (54.3%) guidance. Of note,
nearly half of ENB index procedures were conducted for
multiple purposes, including 33.4% with lymph node sta-
ging (primarily EBUS-guided) and 21.0% with fiducial
markers placed. Tissue adequacy for molecular genetic test-
ing was also high (80.0%) and similar to prior studies [23].
These results suggest that, in unrestricted practice settings,
ENB is used to diagnose peripheral lung nodules and
perform concurrent linear EBUS-guided mediastinal lymph
node staging in a single anesthetic event, facilitating a
multidisciplinary, comprehensive patient care approach.
A third objective of this interim analysis was to provide
a preliminary look at ENB performance. From a patient
perspective, all important follow-up cadence and treat-
ment decisions are made within the 30-day window after
the diagnostic procedure. At the 1-month time-point,
ENB provided a preliminary malignant diagnosis in 45.8%
of subjects, including 40.1% with lung cancer. The initial
45.8% malignancy rate in NAVIGATE is consistent with
other recent ENB publications reporting malignancy rates
of 35–60% [24–27], and is expectedly higher than the
3.7% positive malignancy rate seen in the National Lung
Screening Trial [13].
One-month follow-up is not sufficient to calculate the
true versus false negative rate or diagnostic yield, as the
true prevalence of lung cancer in this population is un-
known at this time. All non-malignant pathology find-
ings require confirmation with longer-term follow-up
or additional diagnostic procedures, depending upon
the pretest probability of malignancy and in accordance
with society guidelines [1, 18]. All follow-up procedures
and final diagnoses will be captured and reported. Early
indicators of clinical stage in NAVIGATE subjects diag-
nosed with lung cancer also suggest a 64% rate of Stage
I-II diagnoses, which are more amenable to surgical
intervention for curative intent. In this observational
study with consecutive enrollment, approximately 36%
of NAVIGATE subjects had Stage III-IV lung cancer.
Diagnostic testing of late-stage patients in NAVIGATE
may reflect not only a lack of standardization for patient
selection but also the changing landscape of personalized
medicine and treatment options for Stage III-IV disease.
Patient selection for ENB, as well as multivariate predic-
tors of safety and effectiveness, will be explored in future
NAVIGATE analyses of the full cohort. This will include
an analysis of Stage III-IV cases to explore the patient,
lesion, and operator/center factors leading to the inclusion
of these cases in the study.
The final objective of this preliminary analysis was to
generate questions for future NAVIGATE analyses and
comparative studies. Unexpected observations included a
high percentage of lesions without a CT bronchus sign
(52%) and a relatively low proportion of subjects in whom
genetic testing was attempted (28%). While current guide-
lines recommend genetic testing for only late-stage disease,
there is extensive variation between institutions. Tissue re-
quirements for comprehensive molecular testing and the
practice of personalized medicine will continue to evolve.
Fig. 3 Lung Cancer Clinical Stage at Diagnosis in Subjects with
Primary Lung Cancer (365 subjects with 395 lesions). Not shown in
graph: One subject had a diagnosis of Stage 0
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Future analyses will describe molecular genetic evaluation
in the NAVIGATE cohort in more detail. Other future
questions include multivariate predictors of safety and
diagnostic yield, factors affecting the need for concur-
rent radial EBUS or other fluoroscopic guidance, usage
patterns of fiducial and pleural dye marking, success
rates of various biopsy tools, and cost effectiveness. In
this way, NAVIGATE will help to set the benchmark for
the ideal ENB patient, and define the procedural techniques
contributing to enhanced performance. Whether ENB
truly enables a shift to an earlier stage diagnosis, and
the impact on long-term patient survival, healthcare
utilization, and costs, will also be topics for future
NAVIGATE analyses.
Limitations
This is a nonrandomized, single-arm analysis of 1-month
interim results. Longer-term follow-up is required to deter-
mine the accuracy of ENB-aided diagnoses, and calculate
diagnostic yield. Follow-up through 24 months is in pro-
gress. This analysis also evaluates only one navigational
bronchoscopy system; other systems are currently available
for clinical use.
Conclusions
This early look at the NAVIGATE results provides infor-
mation about usage patterns and utility of ENB in a large,
unrestricted, generalizable population across diverse prac-
tice settings. In the first 1,000 subjects enrolled, 1-month
follow-up demonstrates low adverse event rates among a
heterogeneous cohort. Continued enrollment and follow-
up will demonstrate the negative predictive value and de-
lineate the patient, lesion, and procedural characteristics
contributing to diagnostic yield. This preliminary analysis
generates questions to be explored in future controlled
clinical studies. Further follow-up will also help define
objective endpoints to guide future population-based
guidelines for intervention.
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